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Abstract  
Purpose: Brittle cornea syndrome 1 (BCS1) is a rare recessive condition characterised by 
extreme thinning of the cornea and sclera, caused by mutations in ZNF469. Keratoconus is 
a relatively common disease characterised by progressive thinning and ectasia of the 
cornea. The aetiology of keratoconus is complex and not yet understood, but rare ZNF469 
variants have recently been associated with disease. We investigated the phenotype of 
BCS1 carriers with known pathogenic ZNF469 mutations, and recruited families in which 
aggregation of keratoconus was observed to establish if rare variants in ZNF469 segregated 
with disease. 
Methods: Patients and family members were recruited and underwent comprehensive 
anterior segment examination including corneal topography. Blood samples were donated 
and genomic DNA was extracted. The coding sequence and splice sites of ZNF469 were 
PCR amplified and Sanger sequenced. 
Results: Four carriers of three BCS1-associated ZNF469 loss-of-function mutations (p.[ 
Glu1392Ter], p.[Gln1930Argfs*6], p.[Gln1930fs*133]) were examined and none had 
keratoconus. One carrier had partially penetrant features of BCS1, including joint 
hypermobility. ZNF469 sequencing in 11 keratoconus families identified 9 rare (MAF≤0.025) 
variants predicted to be potentially damaging. However, in each instance the rare variant(s) 
identified, including two previously reported as potentially keratoconus-associated, did not 
segregate with the disease.  
Conclusions: The presence of heterozygous loss-of-function alleles in the ZNF469 gene did 
not cause keratoconus in the individuals examined. None of the rare non-synonymous 
ZNF469 variants identified in the familial cohort conferred a high risk of keratoconus, 
therefore, genetic variants contributing to disease pathogenesis in these 11 families remain 
to be identified.  
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INTRODUCTION 
Keratoconus (OMIM #148300) is characterized by progressive corneal thinning and ectasia, 
leading to irregular astigmatism, impairment of visual function and reduced quality of life 1. It 
is a relatively common condition, affecting approximately 1 individual per 1,000 2 although it 
is markedly more frequent in some ethnic groups. It typically presents in the teens or early 
twenties with progression until the fourth decade. Keratoconus is the single most common 
reason for corneal transplantation in the developed world, but the aetiology and 
pathophysiology of this complex disease is not understood 3.  
Although the majority of patients with keratoconus have sporadic disease, familial clustering 
and a high concordance among monozygotic twins imply that genetic factors are likely to 
contribute to disease pathogenesis 4, 5. Identification of the underlying genetic risk factors 
that contribute to the development of keratoconus presents an opportunity to understand the 
underlying disease processes.  
Different approaches have been used to identify risk loci and genes for keratoconus, 
including linkage analysis and candidate gene screening 3. Genome-wide association 
studies (GWAS) have identified common variants associated with keratoconus 6-9, but the 
actual causal variants tagged by GWAS hits and the associated underlying molecular 
mechanisms remain unknown. As for nearly all complex traits, GWAS associated variants 
explain only a limited fraction of the disease heritability. Additional factors, including rare 
variants with stronger effect and not tagged by GWAS SNPs could plausibly account for 
some of the unexplained heritability. While the lack or robust linkage data suggests that 
highly penetrant variants are rare in keracotonus families, variants that increase disease risk 
by about four fold are likely to generate inconsistent evidence for linkage and may therefore 
have been missed 10, 11. 
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There has also been much interest in defining risk loci associated with the highly heritable 
quantitative trait central corneal thickness (CCT) 12, because reduced CCT is a risk factor for 
primary open-angle glaucoma and myopia, and axial myopia and progressive corneal 
thinning are features of keratoconus 9, 13. SNPs located in an intergenic region upstream of 
ZNF469 have been associated with CCT by numerous GWAS in different populations 9, 14-18.  
Importantly, a recent genome wide meta-analysis for CCT identified the major (A) allele of 
rs9938149 (allele frequency = 0.75; 1000Genomes phase I genotyping data), which is 
located approximately 162 kb upstream of ZNF469, to be significantly associated with 
increased CCT and keratoconus 9. This association with keratoconus was validated in an 
independent case control study 19. This finding is somewhat counterintuitive, as one might 
expect that an allele associated with keratoconus would more likely be associated with 
reduced, instead of increased, CCT 9.  
The association of a SNP upstream of ZNF469 with risk of keratoconus is of potential 
biologically relevance, since bi-allelic non-synonymous mutations in ZNF469 cause 
autosomal recessive Brittle Cornea Syndrome (BCS) type 1 20. BCS1 (OMIM #229200) is a 
connective tissue disorder characterised by extreme thinning and fragility of the cornea, joint 
hypermobility and hyperelasticity of the skin, often leading to corneal rupture after minor 
trauma 20.  BCS type 2 (OMIM #614170) is caused by bi-allelic mutations in PRDM5. Ocular 
and systemic phenotypes have been observed in some heterozygote PRDM5 carriers, who 
have blue sclera and small joint hypermobility as well as mildly reduced CCT (range 480-505 
µm, n= 6) 21. Interestingly one of these six individuals also had keratoconus 21. It has not yet 
been determined if heterozygous carriers of BCS1-associated ZNF469 mutations display a 
carrier phenotype, such as reduced CCT or keratoconus, although blue sclera was 
previously documented in one of three molecularly confirmed carriers 22.  
Given the association of rs9938149 (A) with keratoconus, and that bi-allelic mutations in 
ZNF469 cause BCS1, it is possible that rare coding and/or splice site variants in ZNF469 
could contribute to the development of keratoconus 23-25. A recent study of ZNF469 in a 
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cohort of unrelated Europeans with keratoconus reported an enrichment of potentially 
pathogenic rare (MAF<0.001) ZNF469 alleles in 12.5% cases (n=112) 26, while another 
study reported an occurrence of rare (MAF<0.01) ZNF469 missense variants at a frequency 
of 23% in a Polynesian and white New Zealand keratoconus cohort (n= 43) 27.  
To evaluate this hypothesis further we recruited a cohort of patients in which there was 
familial clustering of keratoconus, indicating that genetic variants of relatively large or 
moderate effect contributed to disease. We determined if any rare variants in ZNF469 were 
present, and if these alleles segregated with familial disease. In addition we thoroughly 
evaluated, for the first time, the corneal phenotype of carriers of BCS1 ZNF469 pathogenic 
mutations. 
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METHODS 
Patient recruitment and diagnostic criteria 
Local research ethics committees approved the study and all investigations were conducted 
in accordance with the principles of the Declaration of Helsinki. Patients and family members 
were ascertained in Moorfields Eye Hospital, London, UK, Moorfields Eye Hospital, Dubai, 
United Arab Emirates, and King Faisal Specialist Hospital, Saudi Arabia. In total, 11 families 
were recruited, comprised of 39 affected patients, 15 unaffected individuals <40 years, 5 
unaffected individuals >40 years and 7 individuals diagnosed as keratoconus suspects (see 
below). After informed consent was obtained, venous blood samples were donated and 
genomic DNA was extracted from peripheral blood lymphocytes.  
All individuals had an anterior segment examination that included corneal topography using 
Pentacam (Oculus, Germany) version 1.20r36 (Saudi) or version 1.20r02 (UK). A diagnosis 
of keratoconus was confirmed if there were clinical features on slit lamp examination of 
either eye of regional corneal thinning, ectasia, or other signs of keratoconus (e.g. Fleischer 
ring, Vogt striae) 28 with confirmation by corneal topography. Previous keratoplasty for 
keratoconus was also considered to be confirmation of disease. For individuals without 
clinical signs of keratoconus three specialists experienced in the interpretation of topography 
who were masked to the patients’ identity reviewed the scans. If there were topographic 
abnormalities in either eye they were assigned a diagnosis of keratoconus suspect, or 
unaffected if the topography was normal 29. Because the onset of keratoconus can be 
delayed, individuals were only assigned a diagnosis of unaffected in they were over the age 
of 40 years.  
Four parents of children with BCS1, previously determined to be heterozygous carriers of 
BCS1-associated mutations 22, 30, had anterior segment examinations including corneal 
topography (Pentacam). They were also questioned regarding systemic clinical features 
previously identified in BCS1 and BCS2, including; poor healing/abnormal scarring, soft 
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skin/easy bruising, prior treatment for dysplasia of the hip, femoral epiphyseal changes, 
scoliosis, small joint hypermobility, fractures, myalgia, abnormal gait, deafness and 
hypercompliant tibial bowing 21.  
PCR and Sanger sequencing 
The coding region and the predicted splice site junctions of ZNF469 was amplified using a 
Go-Taq Long PCR master mix (Promega, Southampton, UK) in 8 overlapping fragments 
ranging from 2-3 kb. Amplimers were subsequently bi-directionally Sanger sequenced using 
a series of internal primers (primer sequences are available on request). ZNF469 cDNA is 
numbered according to the reference sequence NM_001127464.1 (which includes a 
potentially coding 84 bp long intronic sequence) and +1 represents the A of the translation 
start codon. 
In silico analysis of ZNF469 variants, control datasets and filtering strategies.  
The allelic frequencies of all variants identified by direct sequencing were cross referenced 
with four independent control databases; (1) NHLBI Exome Sequencing Project (ESP) 
dataset (release Version v.0.0.25, accessed August 2014); (2) 1000 Genomes (1KG) 
dataset (release version 14); (3) whole exome sequencing (WES) data for 521 individuals of 
Saudi Arabian decent with a variety of Mendelian conditions (SA WES); (4) 1,100 individuals 
of varying ethnicity analyzed by WES at UCL (UCL WES).  
The predicted biological effect of rare non-synonymous variants identified in ZNF469 were 
scored for likely pathogenicity utilizing SIFT (http://sift.jcvi.org/), PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/), and Blosum62 
(http://www.ncbi.nlm.nih.gov/Class/FieldGuide/BLOSUM62.txt).  
Sequence data was filtered using two alternative approaches. Filter strategy 1- the following 
variants were removed: (1) all synonymous variants, (2) all variants with a MAF >0.001 in 
the 1KG dataset, (3) all variants with a MAF >0.001 in ESP dataset, (4) all variants predicted 
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to be tolerated by SIFT. Filter strategy 2 - the following variants were removed:  all 
synonymous variants, (2) all variants with a MAF >0.025 in the 1KG dataset, (3) all variants 
with a MAF >0.025 in ESP dataset, and (4) all variants with a MAF >0.025 in our control 
WES datasets. 
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RESULTS 
BCS1 mutation carriers 
The parents of a BSC1 patient, previously determined to be compound heterozygous for 
disease-associated ZNF469 alleles c.[5788delC];[5788dupC] (p.[Gln1930Argfs*6]; 
p.[Gln1930fs*133]) 30, were clinically examined. The mother and father were found to be 
heterozygous carriers of c.5788delC and c.5788dupC, respectively 30. Ophthalmic 
examination showed they were emmetropic, and slit lamp examination of the cornea and 
anterior segment was normal. Corneal topography showed that the mother, age 39 years, 
(BCS1 carrier 1 in Figure 1) had CCT measurements within the normal range, of 567 µm 
(right eye) and 582 µm (left eye) with borderline lack of concordance between the point of 
maximum curvature and the point of maximum corneal elevation (1.01 mm right eye; 1.08 
mm left eye, normal <1.0 mm) with no evidence of keratoconus. The father, age 43 years, 
(BCS1 carrier 2 in Figure 1) had CCT measurement of 510 µm right eye and 503 µm left 
eye. Topography of the right eye showed an asymmetric bow-tie pattern of astigmatism, with 
concordance between the anterior and posterior maximum elevation, and a 0.84 mm 
displacement of the corneal apex from the location of the thinnest point . On the left side, 
although there was a symmetric bow-tie pattern of astigmatism, there was a lack of 
concordance between the point of maximum curvature and the point of maximum corneal 
elevation, with a 1.20 mm displacement of the corneal apex from the location of the thinnest 
point. The CCT measurements of the father are in the range reported for mild keratoconus 
(CCT= 503± 34.15 µm)31, and, in combination with the mild abnormalities in contour, are 
consistent with keratoconus suspect in the left eye. The father also had small joint 
hypermobility (double jointed fingers and wrist) and his sports activity was limited due to 
recurrent ankle dislocation; no additional systemic features were noted in either parent. In 
combination, these data suggest that in the father the c.5788dupC, p.(Gln1930fs*133) 
ZNF469 allele is partially penetrant.  
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Similarly, the heterozygous carrier parents of two affected children homozygous for the 
BCS1-associated ZNF469 allele, c.4174G>T p.(Glu1392X) were examined 22. The father 
was emmetropic, the mother	   had mild stable astigmatism. They both presented with a 
normal slit lamp examination of the cornea and anterior segment. Corneal topography of the 
father (BCS1 carrier 3 in Figure 1), age 40 years, was normal with CCT measurements of 
510 µm (right eye) and 503 µm (left eye). Corneal topography of the mother (BCS1 carrier 4 
in Figure 1), age 42 years, was normal with a symmetric bow-tie pattern of corneal 
astigmatism and CCT measurements of 543 µm (right eye) and 541 µm (left eye). There 
were no topographic features of keratoconus in either parent. The father had complained of 
lower back pain for the last 7 years. He also had bilateral lower foot pain that lasted for an 
hour before his going to sleep. There were no additional systemic features associated with 
BCS1 reported in either parent. In both sets of parents the variation in the direction of CCT 
measurement compared to the adult population (mean 535± 31 µm) 32 was inconsistent. 
Familial keratoconus cohort 
Given that bi-allelic mutations in ZNF469 are associated with BCS1 20, that common variants 
close to ZNF469 are associated with reduced CCT 9, 14-18 and keratoconus risk 9, 19, and the 
recent observation that rare alleles are enriched in keratoconus cases 26, 27, we wanted to 
determine if rare ZNF469 variants were present and associated with increased risk in a 
familial keratoconus cohort. We reasoned that identification and recruitment of families in 
which occurrence of keratoconus cannot readily be accounted for by chance, would offer an 
opportunity to identify rare alleles of moderate or relatively large effect compared to a 
consecutive series of unrelated individuals. We therefore assembled a cohort of eleven 
families, each comprising two or more first-degree relatives affected with keratoconus, and 
screened the coding sequence and splice sites of ZNF469 by direct sequencing. 
Of the eleven families (Figure 2 and 3), six families of Middle Eastern origin had evidence of 
consanguinity and presented with an inheritance pattern consistent with risk alleles 
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conferring an apparent autosomal recessive mode of inheritance (Families 1-6, Figure 2). 
For the remaining families, of mixed ethnicities, affected individuals were identified in more 
than one generation (with the exception of Family 9), consistent with a suggestive autosomal 
dominant (Families 7-11, Figure 3) or potentially pseudo-dominant (Family 10) inheritance 
pattern for predisposing alleles. In total, the cohort included 39 keratoconus patients, 15 
unaffected relatives under 40 years of age, 5 unaffected relatives over 40 years of age and 7 
individuals assigned a diagnosis of keratoconus suspect. All ZNF469 sequence variants 
identified are listed in Table S1.   
Initially, with the aim of identifying any rare and potentially deleterious variants in the 
keratoconus familial cohort, we applied a stringent filtering strategy (Filter strategy 1) similar 
to that applied by Lechner and colleagues 26 filtering out the following variants: (1) all 
synonymous variants, (2) all variants with a MAF >0.001 in the 1KG dataset, (3) all variants 
with a MAF >0.001 in ESP dataset, (4) all variants predicted to be tolerated by SIFT. Using 
this stringent filtering strategy we identified 5 rare ZNF469 variants predicted to be 
potentially deleterious using SIFT (Table 1). However, 3/5 of these variants [c.4337C>T, 
p.(Ala1446Val), c.2035G>A, p.(Glu679Lys) and c.9011_9025del p.(Leu3004_Thr3008del)] 
were present with a MAF >0.001 in our in-house control data sets (UCL WES, SA WES)  
and therefore failed to meet the set criteria (Table 1). The in-frame deletion, 
p.(Leu3004_Thr3008del), has been previously described to be potentially pathogenic 26. 
Interestingly, we observed this variant in the heterozygous state in one individual affected 
with keratoconus (IV:2 in family 5; Figure 2) but was absent in his affected brother (IV:1 in 
family 5, Figure 2). Furthermore, the variant was inherited from his unaffected mother who is 
over 40 years of age (III:2 in family 5, Figure 2). We also observed the same variant in two 
unaffected members of Family 9, one female over 40 years (II:4) and her unaffected son 
(III:3) under 40 years of age (Figure 3). These data demonstrate that this allele is a 
polymorphism that, in isolation, does not confer substantial risk of keratoconus. The 
p.(Glu679Lys) variant with a UCL and SA WES MAF of 0.0049  and 0.0030, respectively 
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(Table 1), is present in the heterozygous state in two affected siblings in Family 1 (Figure 2). 
Unfortunately, other familial DNA samples were not available, but at least one parent is 
expected to carry this allele, and neither have keratoconus. Similarly, the p.(Ala1446Val) 
variant with a UCL and SA WES MAF of 0.0122 and 0.0236, respectively (Table 1), was 
found to be homozygous in an affected individual (II:2), and two unaffected individuals (II:3, 
II:4) in Family 3 (Figure 2). 
Only 2 variants survived this filtering strategy, c.664G>C,	  p.(Gly222Arg) and  c.5624G>A, 
p.(Arg1875His), identified in Families 3 and 8, respectively (Figure 2 and 3).  The 
p.(Gly222Arg) variant was identified in the heterozygous state in only one of two affected 
male siblings in Family 3, and although at least one parent probably carries this allele, 
neither were affected, so this variant did not segregate with keratoconus in this family. The 
p.(Arg1875His) variant was identified in several affected members of Family 8 in either the 
heterozygous state (II:5, II:6 and III:4) or homozygous state (II:11). It was also present in the 
heterozygous state in two family members who are keratoconus suspect; III:3 (age 38 years) 
and III:7 (age 24 years), and an unaffected individual III:6 (age 27 years) in the homozygous 
state. The possibility that all three of these individuals will develop keratoconus cannot 
currently be fully excluded, as disease onset can be delayed. It is also interesting to note 
that an affected family member (II:10) was wild-type for this allele, however it is possible that 
this individual may be a phenocopy. 
For comparison purposes the assembled UCL WES dataset, comprising WES data for 1,100 
individuals of mixed ethnicity with full coverage of the ZNF469 gene (used as a control 
cohort for filtering purposes, as described above) was also filtered according to Filter 
Strategy 1. Interestingly, we identified 4 heterozygous presumed loss-of-function variants 
(stop or frameshift) and 224 non-synonymous variants in ZNF469.  
Given that keratoconus is a relatively common condition 2, we next assessed the genetic 
load of ZNF469 alleles (Table S1) with a more relaxed filtering criteria, such that one or more 
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potentially deleterious variants of moderate effect, present at low frequency in the normal 
population, would not be excluded. For this analysis we filtered out the following variants: (1) 
all synonymous variants, (2) all variants with a MAF >0.025 in the 1KG dataset, (3) all 
variants with a MAF >0.025 in ESP dataset, and (4) all variants with a MAF >0.025 in our 
control WES datasets. This alternative filtering strategy highlighted a further 4 variants of 
potential interest [(c.1697C>T p.(Ala566Val); c.2803G>A, p.(Glu935Lys); c.6956C>T, 
p.(Ala2319Val); c.10277G>A, p.(Arg3426Gln)] in families 1, 3, and 10 (Table 2; Figures 2 
and 3).  
The p.(Ala566Val) variant was identified in one of the affected siblings in Family 1 (V:5, 
Figure 2), but both parents are unaffected. This p.(Ala566Val) variant was also identified in 
two unaffected members of Family 3 under 40 years of age (II:3 and II:4) and one of their 
affected siblings (II:1), the parents, at least one of which is expected to carry the allele, are 
also unaffected in this family. Interestingly, the variant has previously been identified in 3 
unrelated sporadic keratoconus patients of Caucasian (n=2) and Indian (n=1) origin 27. The 
segregation data present here for Families 1 and 3 suggest this allele, in isolation, does not 
confer substantial risk of disease. Two rare heterozygous variants were identified in Family 
10, c.6956C>T, p.(Ala2319Val) and c.10277G>A, p.(Arg3426Gln) (Table 2).  All affected 
individuals (II:1, III:2, III:4) share the p.(Arg3426Gln) variant, as does unaffected individual 
III:3 (32 years of age). Both the affected father (II:1) and the unaffected mother (II:2), who 
are related, are heterozygous for the c.6956C>T, p.(Ala2319Val) variant, and this allele was 
not inherited by their affected children (III:2 and III:4). The p.(Glu935Lys) variant was 
identified in Family 1 in only one of two affected siblings with unaffected parents (Figure 2). 
In Families 2, 4, 6, 7 and 11 no rare variants were identified that passed either of the filtering 
criteria applied (Figure 2 and 3). 
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DISCUSSION 
 
BCS1 is an autosomal recessive condition characterized by extreme corneal fragility, often 
leading to corneal rupture after minor trauma, in addition to other features such as joint 
hyperextensibility. Given the rarity of this condition, the occurrence of phenotypes in parents 
of affected individuals, who are heterozygous ZNF469 mutation carriers, has not previously 
been fully assessed. Here, we examined four carriers of three different presumed loss-of-
function heterozygous BCS1 pathogenic mutations; p.(Glu1392X), p.(Gln1930Argfs*6) and 
p.(Gln1930fs*133). The carriers had an age range of 39-43 years and none had 
keratoconus. One carrier of the c.5788dupC, p.(Gln1930fs*133) allele, age 43 yrs (BCS1 
carrier 2 in Figure1), who was keratoconus suspect in one eye, also had small joint 
hypermobility and recurrent ankle dislocation suggestive of partial penetrance of BCS. A 
keratoconus suspect is an individual with minor changes in corneal shape that are features 
of keratoconus, which are only detectable with corneal topography, and without clinical 
disease. These changes may be non-progressive and because of the age of this individual, 
it is highly likely that they will not progress. BCS1 carrier 3 (Figure 1) was also noted to 
suffer from back and bilateral lower foot pain which may or may not represent partially 
penetrant features of BCS. This investigation of BCS1 carriers leads us to conclude that 
loss-of-function ZNF469 alleles in the heterozygous state (i.e. presumed haploinsufficiency 
of ZNF469) do not cause keratoconus, but carriers of recessive mutations could present with 
partially penetrant features of BCS.  
 
We observed 9 rare (MAF≤ 0.025) coding ZNF469 variants in our familial keratoconus cohort 
that were predicted to be potentially damaging by one or more bioinformatic tools (Table 2). 
Interestingly, two of these variants have been previously reported to be pathogenic 
mutations causing keratoconus in the heterozygous state; p.(Leu3004_Thr3008del) and 
p.(Ala566Val) 26, 27. However, we observed the p.(Leu3004_Thr3008del) variant (UCL WES 
cohort MAF=0.0068; SA WES cohort MAF=0.0089) in the heterozygous state in 3 unaffected 
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individuals in our familial cohort, and inheritance of the p.(Ala566Val) variant (UCL WES 
cohort MAF=0.0119; SA WES cohort MAF=0.0020) was not consistent with a high risk of 
developing keratoconus in two families. These variants are therefore most likely polymorphic 
alleles that, in isolation, do not confer a substantial risk of keratoconus. 
Known ZNF469 loss-of-function mutations in the heterozygous state, as observed in the 
carriers of BCS1 mutations, are not sufficient to cause keratoconus. Therefore, ZNF469 
variants that could predispose an individual to a high risk of developing keratoconus, when in 
the heterozygous state, must have a gain-of-function or a dominant-negative effect on the 
normal gene/protein function. However, segregation analysis revealed that none of the 
remaining non-synonymous variants were consistent with such an allele having a dominant 
mechanism of disease, even allowing for reduced penetrance.  
Importantly, interrogation of our in-house WES dataset for 1,100 individuals of mixed 
ethnicity (UCL WES), by applying the same stringent filtering criteria (Filtering strategy 1) we 
applied initially to our keratoconus family data we identified 4 heterozygous presumed loss-
of-function variants (stop or frameshift) and 224 non-synonymous variants in the ZNF469 
gene, illustrating the allelic variability of this large gene.  
Our data suggest that the allelic variation of ZNF469 in the general population is somewhat 
under-represented in currently available public databases (EVS and 1000 Genomes), 
perhaps due to poor coverage of the gene using previous generation WES capture 
techniques. Our extensive UCL WES internal control dataset (n=1,100), in combination with 
the familial cohort we have studied likely contributes to the differences observed between 
our study and others 26, 27.   
Our understanding of the functional role of ZNF469 in the cornea, or other tissues, and the 
mechanisms that mediate the development and maintenance of the structural integrity of the 
cornea is limited. ZNF469 is a relatively polymorphic gene that is poorly conserved amongst 
lower mammals and vertebrates 20. It is thought to function as a nuclear transcription factor 
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regulating extracellular matrix protein expression in the cornea, or as an extra-nuclear 
regulatory molecule involved in the synthesis and/or organization of extracellular matrix 
proteins 20, 21, 30. The functional impact of rare ZNF469 variants can only be established once 
more is known about the role of ZNF469 in the human cornea. 
In the absence of a functional assay and given the relatively polymorphic and poor 
evolutionary conservation of ZNF469, performing segregation analysis in familial cohorts to 
evaluate whether a variant confers a substantial risk of disease is extremely valuable. The 
lack of segregation of any of the rare variants identified in our study suggests that they do 
not, in isolation, confer a substantial risk of disease. However, rare ZNF469 variants may still 
contribute to mutational load or the genetic architecture of keratoconus. 
The keratoconus families described here, some with many affected individuals (e.g. Family 8 
with 6 affected individuals in 2 generations) offer an opportunity to utilise next generation 
sequencing (NGS) approaches to identify the genetic factors that are involved in the risk of 
developing keratoconus. Given the consanguineous nature of families 1-6, and the potential 
autosomal recessive inheritance patterns of keratoconus observed, autozygosity mapping in 
combination with NGS may prove to be a powerful way to determine keratoconus associated 
variants in these families.  
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FIGURE LEGENDS 
Figure 1. Computer generated analysis of Scheimpflug images of, heterozygous 
carriers of pathogenic BCS1 ZNF469 alleles compared to a keratoconus patient. For 
each individual the axial/sagittal curvature of the anterior corneal surface (row 1), the 
regional corneal thickness (row 2), the anterior corneal surface elevation compared to the 
mean anterior elevation (row 3), and posterior corneal surface elevation compared to the 
mean posterior elevation (row 4) of the left eye are presented. In the keratoconus patient 
there is marked thinning and steepening of the curvature of the anterior and posterior 
surfaces of the central cornea. BCS1 carrier 1 (p.[Gln1930Argfs*6]) has nasal displacement 
of the point of maximum curvature of the anterior corneal surface but no other abnormality. 
In BCS1 carrier 2 (p.[Gln1930fs*133]) there is a symmetric bow-tie pattern of astigmatism on 
the anterior curvature, but with a lack of concordance between the point of maximum 
curvature of the anterior surface compared to the point of maximum elevation, with a 
displacement of the corneal apex from the thinnest location of 1.20 mm. BCS1 carrier 3 
(p.[Glu1392X])  (column 5) appeared normal, while and BCS1 carrier 4 (p.[Glu1392X]) 
(Column 6) had a symmetric bow-tie pattern of corneal astigmatisms but was otherwise 
normal.  The topography of normal individuals are shown for comparison (columns 4 and 7). 
The apex of the cornea of BSC1 carrier 3 and control B are decentered but the elevation 
maps are within normal limits. All images were acquired using Pentacam (Oculus, 
Germany). Data for columns 1-4 were analyzed using software version 1.20r02. Data for 
columns 5-7 were analyzed using a software version 1.20r36.   
Figure 2. Segregation of rare ZNF469 coding variants in consanguineous keratoconus 
families with affected individuals in one generation 
Pedigrees of Families 1-6 of Middle Eastern origin are shown. A diagnosis of keratoconus 
was given if there were clinical features on slit lamp examination in either eye of regional 
corneal thinning, ectasia, or other signs of keratoconus, with confirmation by corneal 
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topography. Documented keratoplasty for keratoconus was also considered diagnostic. 
Individuals were assigned a diagnosis of keratoconus suspect, denoted as ‘S’, on the basis 
of presence of topographic abnormalities in either eye, or unaffected if the topography was 
normal. All unaffected individuals under the age of 40 years are denoted with a ‘?’ as onset 
of keratoconus can be delayed. Segregation of rare ZNF469 alleles presented in Tables 1 
and 2 are shown. Het = heterozygous state; Homo = homozygous state; WT= wild-type.  
Figure 3. Segregation of rare ZNF469 coding variants in keratoconus families with 
affected individuals in more than one generation and non-consanguineous families 
Pedigrees of Families 7-11 are shown. A diagnosis of keratoconus was given if there were 
clinical features on slit lamp examination in either eye of regional corneal thinning, ectasia, 
or other signs of keratoconus, with confirmation by corneal topography. Documented 
keratoplasty for keratoconus was also considered diagnostic. Individuals were assigned a 
diagnosis of keratoconus suspect, denoted as ‘S’, on the basis of presence of topographic 
abnormalities in either eye, or unaffected if the topography was normal. All unaffected 
individuals under the age of 40 years are denoted with a ‘?’ as onset of keratoconus can be 
delayed.  Segregation of rare ZNF469 alleles presented in Tables 1 and 2 are shown. Het = 
heterozygous state; Homo = homozygous state; WT= wild-type.  
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